Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $15.60.
A number of analysts recently weighed in on FOMX shares. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 7th. Cowen set a $30.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 1st. HC Wainwright set a $12.00 target price on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 28th. Barclays started coverage on shares of Foamix Pharmaceuticals in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $10.00 target price on the stock. Finally, ValuEngine cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th.
In other Foamix Pharmaceuticals news, Director Anna Kazanchyan sold 10,600 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $2.61, for a total value of $27,666.00. Following the transaction, the director now directly owns 55,955 shares in the company, valued at $146,042.55. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 19,911 shares of company stock worth $62,582. Company insiders own 2.95% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in FOMX. Perceptive Advisors LLC boosted its position in Foamix Pharmaceuticals by 50.0% in the fourth quarter. Perceptive Advisors LLC now owns 4,661,824 shares of the specialty pharmaceutical company’s stock valued at $15,850,000 after buying an additional 1,554,400 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Foamix Pharmaceuticals by 134.7% during the fourth quarter. Stonepine Capital Management LLC now owns 1,293,177 shares of the specialty pharmaceutical company’s stock worth $4,643,000 after purchasing an additional 742,099 shares in the last quarter. Knott David M acquired a new position in shares of Foamix Pharmaceuticals during the fourth quarter worth approximately $740,000. Sofinnova Investments Inc. lifted its position in shares of Foamix Pharmaceuticals by 24.5% during the fourth quarter. Sofinnova Investments Inc. now owns 832,293 shares of the specialty pharmaceutical company’s stock worth $2,987,000 after purchasing an additional 163,674 shares in the last quarter. Finally, Diag Capital Management LP acquired a new position in shares of Foamix Pharmaceuticals during the fourth quarter worth approximately $960,000. Hedge funds and other institutional investors own 56.38% of the company’s stock.
Shares of NASDAQ:FOMX traded up $0.01 on Tuesday, hitting $2.60. 2,896 shares of the company were exchanged, compared to its average volume of 266,254. The firm’s 50 day moving average price is $2.64. Foamix Pharmaceuticals has a one year low of $2.30 and a one year high of $7.60. The stock has a market capitalization of $140.97 million, a price-to-earnings ratio of -1.52 and a beta of 1.74.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). Foamix Pharmaceuticals had a negative return on equity of 79.46% and a negative net margin of 2,115.11%. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.95 million. Equities analysts forecast that Foamix Pharmaceuticals will post -1.61 earnings per share for the current fiscal year.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Further Reading: Oversold
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.